Last reviewed · How we verify

IMX-110 combined with Tislelizumab

Immix Biopharma, Inc. · Phase 1 active Small molecule

IMX-110 combined with Tislelizumab is a Small molecule drug developed by Immix Biopharma, Inc.. It is currently in Phase 1 development. Also known as: One Arm.

At a glance

Generic nameIMX-110 combined with Tislelizumab
Also known asOne Arm
SponsorImmix Biopharma, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IMX-110 combined with Tislelizumab

What is IMX-110 combined with Tislelizumab?

IMX-110 combined with Tislelizumab is a Small molecule drug developed by Immix Biopharma, Inc..

Who makes IMX-110 combined with Tislelizumab?

IMX-110 combined with Tislelizumab is developed by Immix Biopharma, Inc. (see full Immix Biopharma, Inc. pipeline at /company/immix-biopharma-inc).

Is IMX-110 combined with Tislelizumab also known as anything else?

IMX-110 combined with Tislelizumab is also known as One Arm.

What development phase is IMX-110 combined with Tislelizumab in?

IMX-110 combined with Tislelizumab is in Phase 1.

Related